Myriad Genetics, Inc. (MYGN), a leading molecular diagnostics company, has announced a commercialization roadmap for its Precise MRD assay.
This groundbreaking technology leverages ultrasensitive circulating tumor DNA detection to provide valuable insights across multiple cancer types.
The company plans a limited launch of Precise MRD with select community-based clinicians in breast cancer starting in March 2026, followed by colorectal and renal cancers later that year. Myriad also aims to expand into ovarian and endometrial cancers from 2027 onward.
Interim clinical studies have demonstrated the assay's ability to detect ctDNA down to one part per million, with high baseline sensitivity and strong predictive power for recurrence and treatment response in breast and colorectal cancers.
These findings have been presented at leading medical conferences and published in peer-reviewed journals, further reinforcing Precise MRD's potential role in real-world precision oncology care.
MYGN is currently trading at $5.77, down 0.69 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.